Koensgen D[Author] - Search Results

Year	Number of Results
2003	2
2006	1
2007	6
2008	4
2009	5
2010	4
2011	2
2013	1
2014	1
2015	2
2016	4
2017	5
2018	3
2021	0

1

Jump in the fire--heat shock proteins and their impact on ovarian cancer therapy.

Stope MB, Koensgen D, Burchardt M, Concin N, Zygmunt M, Mustea A. Stope MB, et al. Among authors: koensgen d. Crit Rev Oncol Hematol. 2016 Jan;97:152-6. doi: 10.1016/j.critrevonc.2015.08.008. Epub 2015 Aug 13. Crit Rev Oncol Hematol. 2016. PMID: 26318096 Review.

2

The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application.

Stope MB, Koensgen D, Weimer J, Paditz M, Burchardt M, Bauerschlag D, Mustea A. Stope MB, et al. Among authors: koensgen d. Arch Gynecol Obstet. 2016 Nov;294(5):889-895. doi: 10.1007/s00404-016-4194-7. Epub 2016 Sep 14. Arch Gynecol Obstet. 2016. PMID: 27637583 Review.

3

Functionality of the Tumor Suppressor microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma.

Stope MB, Cernat V, Kaul A, Diesing K, Koensgen D, Burchardt M, Mustea A. Stope MB, et al. Among authors: koensgen d. Anticancer Res. 2018 Mar;38(3):1547-1550. doi: 10.21873/anticanres.12383. Anticancer Res. 2018. PMID: 29491084

4

Characterization and Management of Borderline Ovarian Tumors - Results of a Retrospective, Single-center Study of Patients Treated at the Department of Gynecology and Obstetrics of the University Medicine Greifswald.

Koensgen D, Weiss M, Assmann K, Brucker SY, Wallwiener D, Stope MB, Mustea A. Koensgen D, et al. Anticancer Res. 2018 Mar;38(3):1539-1545. doi: 10.21873/anticanres.12382. Anticancer Res. 2018. PMID: 29491083

5

Polymorphism of the IL-8 gene and the risk of ovarian cancer.

Koensgen D, Bruennert D, Ungureanu S, Sofroni D, Braicu EI, Sehouli J, Sümnig A, Delogu S, Zygmunt M, Goyal P, Evert M, Olek S, Biebler KE, Mustea A. Koensgen D, et al. Cytokine. 2015 Feb;71(2):334-8. doi: 10.1016/j.cyto.2014.07.254. Epub 2014 Aug 21. Cytokine. 2015. PMID: 25151495

6

Drug-induced Modulation of Heat Shock Protein HSPB1 in an Ovarian Cancer Cell Model.

Stope MB, Wiegank L, Weiss M, Diesing K, Koensgen D, Burchardt M, Zygmunt M, Mustea A. Stope MB, et al. Among authors: koensgen d. Anticancer Res. 2016 Jul;36(7):3321-7. Anticancer Res. 2016. PMID: 27354589

7

The Tumor Suppressor MicroRNA-1 Exhibits Restricted Inhibition of Proliferation of Ovarian Cancer Cells.

Stope MB, Hettenbach D, Kaul A, Paditz M, Diesing K, Burchardt M, Zygmunt M, Mustea A, Koensgen D. Stope MB, et al. Among authors: koensgen d. Anticancer Res. 2016 Jul;36(7):3329-34. Anticancer Res. 2016. PMID: 27354590

8

Y-box Binding Protein-1 Enhances Oncogenic Transforming Growth Factor β Signaling in Breast Cancer Cells via Triggering Phospho-Activation of Smad2.

Stope MB, Weiss M, Koensgen D, Popp SL, Joffroy C, Mustea A, Buck MB, Knabbe C. Stope MB, et al. Among authors: koensgen d. Anticancer Res. 2017 Dec;37(12):6745-6748. doi: 10.21873/anticanres.12134. Anticancer Res. 2017. PMID: 29187452

9

Expression and localization of e-cadherin in epithelial ovarian cancer.

Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J. Koensgen D, et al. Anticancer Res. 2010 Jul;30(7):2525-30. Anticancer Res. 2010. PMID: 20682978

10

Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.

Koensgen D, Stope MB, Tuerbachova I, Bruennert D, Kohlmann T, Braicu I, Sehouli J, Denkert C, Darb-Esfahani S, Stickeler E, Sofroni D, Dahl E, Mustea A. Koensgen D, et al. Gynecol Obstet Invest. 2018;83(5):508-514. doi: 10.1159/000479027. Epub 2017 Jul 22. Gynecol Obstet Invest. 2018. PMID: 28738361

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results